“…The following antibodies were used: mAb W6/32 (Barnstable et al, 1978), recognizing properly folded human class I complexes; mAb HC10 , specific for human class I free heavy chains (HCs); antihuman HC serum (Stam et al, 1986), specific for free human HCs; antimouse HC serum (Machold et al, 1995), recognizing free HCs only; anti-p8 serum (raised in our laboratory, according to Smith et al [1986], against a synthetic peptide representing the most COOH-terminal exon of the H-2K b molecule); anti-human 132m serum (raised against highly purified [~2 m, separated from HLA-A2 and HLA-A28 by gel filtration in acetic acid); rabbit anti-ER serum provided by Dr. D. Louvard (Institut Pasteur, Paris, France) (Louvard et al, 1982); mouse monoclonal anti-PDI (ID3) provided by Dr. S. Fuller (EMBL, Heidelberg, Germany) (Vaux et al, 1990); rabbit anti-bovine cathepsin D provided by Dr. G. Jaureguiberry (IN-SERM U.13, Hopital Claude Bernard, Paris, France) (Bailly et al, 1991); mouse monoclonal anti-ERGIC 53 provided by Dr. H. P. Hauri (University of Basel, Basel, Switzerland) (Schweizer et al, 1988); rabbit polyclonal affinity purified anti-human ubiquitin and mouse monoclonal anti-E1 provided by Dr. A. Schwartz (Washington University, St. Louis, MO) (Schwartz et al, , 1992. To visualize the primary antibodies nondirectly reactive with protein A, rabbit anti-mouse IgG and rabbit antimouse IgM (Nordic Immunochemicals, Tilburg, The Netherlands) were used.…”